On December 26, 2014, Taizhou Biopredio Biotechnology Co., Ltd was established. The company is located in the third floor, NO.51, the fourth phase of China Pharmaceutical City, Taizhou, Jiangsu Province. It is a wholly foreign-owned enterprise. Tao Wenjing, the legal representative, is also the executive director and general manager of the company. The company is mainly engaged in the R & D, production and sales of class II and class III medical devices (including biological diagnostic reagents) and scientific reagents, as well as the development of testing technology services and the sales of second and third class medical devices as agents.
On April 15, 2016, the company successfully absorbed and merged Taizhou Huaji Biotechnology Co., Ltd., which was changed into a Sino foreign joint venture. Three investors, Wang Fengshun, Huang Aihua and Jiang Lixin, were introduced, with an investment of more than 7 million yuan. Tao Wenjing was the legal representative, chairman and general manager of the company.
On November 4, 2016, the name of the company was changed to " BioPredia BioTech Co., Ltd" and the registered capital was changed to RMB 10 million.
On May 3, 2017, the company successfully introduced venture capital - Hangzhou Chende investment partnership (limited partnership) and Guangzhou Jinyuan investment management partnership (limited partnership, Guangzhou Jinyu inspection group as the main investor and operation manager) and carried out industrial and commercial registration, completed equity financing of tens of millions of yuan, with registered capital changed to 13.6364 million yuan; Tao Wenjing, Huang Aihua, Tao Fangyu, Wang Fengshun and Wu Jialu are members of the board of directors for the company, Tao Wenjing is the chairman, general manager and legal representative of the company.
On August 7, 2017, six samples of registered sex hormone liquid phase chip kit were completed.
On October 30, 2017, the provincial Medical apparatus and Instruments Inspection Branch carried out a type-test of six liquid-phase microchip kits for sex hormones.
From June 7, 2018, the clinical trail of six joint detection kits for sex hormones were initiated in the first hospital of Nanjing and the Second Affiliated Hospital of Nanjing Medical University, and the trials were fully completed on February 21, 2019.
On July 15 and 16, 2019, Taizhou Inspection Branch of Jiangsu Provincial Drug Administration sent system assessment experts to conduct on-site assessment on the establishment and operation of the company's quality system. On The 31st of the same month, the system review was completed and passed.
On October 31, 2019, Jiangsu Food and Drug Administration approved the product registration certificate of six joint test kits for sex hormones (flow cytometry) with the license number of 20192401245 and the validity period is 5 years.
On December 31, 2019, Jiangsu Provincial Drug Administration approved the production license for medical devices with the license number 20190163, and the validity period is 5 years.
On September 17, 2021, the company established Suzhou pandi Biotechnology Co., Ltd. wholly-owned in Wuzhong District, Suzhou. Its registered address is: unit 07/08, 6th floor, building a, No. 5 Xinghan street, Suzhou Industrial Park, with a registered capital of 2million yuan. It is mainly responsible for the research and development, registration and product sales of test kits. Taowenjing is the legal representative, executive director and general manager.
In April 2022, PEDI biological cytokine calibrators and quality control products successively obtained class II Registration Certificates for medical devices (sxzz 2022401093, sxzz 20222401062).
